Array biopharma to present at the leerink swann global healthcare conference

Boulder, colo.--(business wire)--array biopharma inc. (nasdaq: arry) today announced that its president and chief scientific officer, kevin koch, will speak at the leerink swann healthcare conference in new york. the public is welcome to participate in the conference through a webcast on the array biopharma website. event: presenter: date: time: location: webcast: www.arraybiopharma.com about array biopharma array biopharma inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer and inflammatory diseases. array has four core proprietary clinical programs: arry-614 for myelodysplastic syndromes, arry-520 for multiple myeloma, arry-797 for pain and arry-502 for asthma. in addition, array has 10 partner-funded clinical programs including two mek inhibitors in phase 2: selumetinib with astrazeneca and mek162 with novartis. for more information on array, please go to www.arraybiopharma.com.
ARRY Ratings Summary
ARRY Quant Ranking